Seralutinib

Seralutinibm (PK-10571, GB002) is a Novel Inhaled Pdgfr Kinase Inhibitor. Seralutinib demonstrates efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah). Localized delivery of GB002 is efficacious on multiple measures of disease activity in the SU5416/H model. GB002 treatment is associated with disease remodeling including improved cardiopulmonary hemodynamics, reduced pulmonary arteriolar muscularization, restoration of BMPR2 signaling, reduced NT-proBNP and improved cytokines.


Cat. No.: EX-A5138	Purity: >98%

	Chemical structure of Seralutinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	550	In-stock
100mg	700	In-stock
200mg	1150	In-stock
500mg	1750	In-stock
1g	2550	In-stock
5g	6300	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	PK-10571
Synonyms 2	GB002
CAS No.	1619931-27-9
Purity	>98%
Formula	C27H27N5O3
Mol Weight	469.535
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Anna Galkin, et al. Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH).
CoA	CoA of Seralutinib


		Search